|
Company:
|
EXELIXIS, INC. (EXEL)
|
|
Form Type:
|
4
|
|
Filing Date:
|
8/5/2022
|
|
CIK:
|
0000939767
|
|
Address:
|
1851 HARBOR BAY PARKWAY
|
|
City, State, Zip:
|
ALAMEDA, California 94502
|
|
Telephone:
|
(650) 837-7000
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$19.51
|
Change:
0.025 (0.13%)
|
Trade Time:
03:05 PM EST
|
Market Cap:
$6.35B
|
|
|
|
|
|
|
Description of Business
|
|
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating
next-generation medicines and combination regimens at the forefront of cancer
care. Through the commitment of our drug discovery, development and
commercialization resources, we have produced four marketed pharmaceutical
products, including our flagship molecule, cabozantinib. We continue to evolve
our product portfolio, leveraging our investments, expertise and strategic
partnerships, to target an expanding range of tumor types and indications with
our clinically differentiated pipeline of small molecules, antibody-drug
conjugates (ADCs) and other biotherapeutics.
Sales related to cabozantinib account for the majority of our revenues.
Cabozantinib is an inhibitor of multiple tyrosine kinases including MET, AXL,
VEGF receptors and RET and has been approved by the U.S.
|
|
|
|